A group of 46 states and Washington, D.C., in the lawsuit accuse 26 drug companies of conspiring to fix generic drug prices and reduce competition, in today's bite-sized hospital and health industry news from Connecticut, Maryland, and Pennsylvania.
Data shows that the rates of newly reported cases of the novel coronavirus are accelerating in 22 states, and some state leaders in response have paused their plans to reopen nonessential businesses and relax social distancing measures—while leaders in other states are warning they might have to reimplement business closures and stay-at-home orders.
23andMe and other genetics companies have faced criticism over a lack of representation of people of color in its genetic databases and leadership, and earlier this month, 23andMe's CEO acknowledged that the company is "part of the problem" when it comes to racial inequities. Here are five ways genetics companies like 23andMe can address those disparities, according to geneticists.
Montefiore Medicine President and CEO Philip Ozuah for months has been working to combat America's new coronavirus epidemic, but in an opinion piece published by the New York Times, Ozuah notes that, as a black man, he also faces "another virus as old as the country itself": racism.
HHS on Friday finalized a rule that will roll back a regulation issued under former President Barack Obama that prohibits health care providers and insurance companies from discriminating against transgender individuals—although a Supreme Court ruling issued Monday regarding transgender workers' rights could affect the new rule's legal footing.